Nossa Missão
97,1%
Nenhum / rastrear PVL1
0,0% PVL1 moderado / grave
0%
TAV-em-TAV
Ruptura anular ou obstrução coronariana2,3
63%
Redução AVC peri-processualtaxa com SENTINEL CPS4
1. Götberg M., MD. One-year outcomes with the transcatheter LOTUS Edge™ Aortic Valve System; PCRLV 2018; London, United Kingdom.
2. Meredith IT, et al. EuroIntervention 2017; 13:788-954.
3. Feldman TE, et al. JAMA 2018; 319:27-37.
4. SENTINEL IDE Trial presented at the SENTINEL CPS FDA Advisory Panel, February 2017.
3. Feldman TE, et al. JAMA 2018; 319:27-37.
4. SENTINEL IDE Trial presented at the SENTINEL CPS FDA Advisory Panel, February 2017.
